Skip to main content
SpringerLink
Log in

Lipid Injectable Emulsions: Pharmacopeial and Safety Issues

  • Expert Review
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Abstract

Lipid injectable emulsions have been routinely used in patients worldwide for over 40 years as a nutritional supplement in patients requiring parenteral nutrition. They can be given as a separate infusion or added into total parenteral nutrition admixtures. Despite such broad use, no pharmacopeial standards exist with respect to the optimal pharmaceutical characteristics of the formulation. Several attempts to establish standard physical and chemical attributes have been attempted by various pharmacopeias around the world, but without success largely due to technical issues regarding the creation of globule size limits. Recently, the United States Pharmacopeia has revised its previous efforts and developed two methods and criteria (under Chapter <729>) to measure the mean droplet size (Method I), and the large-diameter tail > 5 μm (Method II) of the globule size distribution to verify the stability of lipid injectable emulsions. Importantly, it is the latter size limits of Method II that have the greatest implications for infusion safety. The major safety issues involving lipid injectable emulsions include impairments in plasma clearance in susceptible patients, and the infusion of an unstable emulsion containing large quantities of potentially embolic fat globules. Recent animal studies investigating the toxicity from the infusion of unstable lipid injectable emulsions have shown evidence of oxidative stress and tissue damage to the liver when recommended globule size limits determined by Method II of the USP are exceeded. Adoption of Chapter <729> of the USP seems appropriate at this time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. R. Gazitua, K. Wilson, B. R. Bistrian, and G. L. Blackburn. Factors determining the peripheral vein tolerance to amino acid infusions. Arch. Surg. 114:897–900 (1979).

    PubMed  CAS  Google Scholar 

  2. J. W. Isaacs, W. J. Millikan, J. Stackhouse, T. Hersh, and D. Rudman. Parenteral nutrition of adults with a 900 milliosmolar solution via peripheral veins. Am. J. Clin. Nutr. 30:522–529 (1977).

    Google Scholar 

  3. Mission and Preface. United States Pharmacopeia 29/National Formulary 24, United States Pharmacopeial Convention, Rockville, MD, 2006. p. v.

  4. Intravenous Fat Emulsion. Proposed monograph. Pharmacopeial preview. Pharm. Forum 17:2201–2204 (1991).

  5. Globule Size Distribution in Intravenous Emulsions (Chapter <728>). Proposed chapter. Pharmacopeial preview. Pharm. Forum 17:2219–2304 (1991).

  6. Globule Size Distribution in Lipid Injectable Emulsions (Chapter <729>). Proposed chapter. In-process revision. Pharm. Forum 30:2235–2240 (2004).

  7. Globule Size Distribution in Lipid Injectable Emulsions (Chapter <729>). Proposed chapter. In-process revision. Pharm. Forum 31:1448–1453 (2005).

  8. Lipid Injectable Emulsion. In-process revision. Pharm. Forum 31(2):416–419 (2005).

  9. Lipid Injectable Emulsion. In-process Revision. Pharm. Forum 32:350–353 (2006).

  10. Intralipid 20%. A 20% I.V. Fat Emulsion in Excel® Container. Product Package Insert, Fresenius Kabi, Uppsala, Sweden.

  11. Liposyn III 20% intravenous fat emulsion. Product package insert. Abbott Laboratories, North Chicago, IL, USA.

  12. C. Washington. The stability of intravenous fat emulsions in total parenteral nutrition mixtures. Int. J. Pharm. 66:1–21 (1990).

    Article  CAS  Google Scholar 

  13. D. F. Driscoll, J. G. Dunbar, and A. Marmarou. Fat globule size in a propofol emulsion containing sodium metabisulfite. Am. J. Health-Syst. Pharm. 61:1276–1280 (2004).

    PubMed  CAS  Google Scholar 

  14. D. F. Driscoll, H. N. Bhargava, L. Li, R. H. Zaim, V. K. Babayan, and B. R. Bistrian. The physicochemical stability of complex intravenous lipid dispersions as total nutrient admixtures. Am. J. Health-Syst. Pharm. 52:623–634 (1995).

    PubMed  CAS  Google Scholar 

  15. D. F. Driscoll, J. Nehne, H. Peterss, K. Klütsch, B. R. Bistrian, and W. Niemann. Physicochemical stability of intravenous lipid emulsions as all-in-one admixtures for the very young. Clin. Nutr. 22:489–495 (2003).

    Article  PubMed  CAS  Google Scholar 

  16. D. F. Driscoll, J. Nehne, R. Franke, H. Peterss, B. R. Bistrian, and W. Niemann. The influence of medium-chain triglycerides on the stability of all-in-one formulations. Int. J. Pharm. 240:1–10 (2002).

    Article  PubMed  CAS  Google Scholar 

  17. C. Washington, and S. S. David. Ageing effects in parenteral emulsions: the role of fatty acids. Int. J. Pharm. 39:33–37 (1987).

    Article  CAS  Google Scholar 

  18. C. J. Herman, and M. J. Groves. The influence of free fatty acid formation on the pH of phospholipids-stabilized triglyceride emulsions. Pharm. Res. 10:774–776 (1993).

    Article  PubMed  CAS  Google Scholar 

  19. K. M. Teelmannn, B. Schlappi, M. Schupbach, and A. Kistler. Preclinical safety evaluation of intravenously administered mixed micelles. Arzneim.-Forsch. 34:1517–1523 (1984).

    Google Scholar 

  20. G. Arenas, R. Del Buono, M. J. Oyarzun, P. Donoso, and D. Quijada. Pulmonary response to free fatty acid intravenous infusion in the rabbit: role of leukotrienes and the effects of prostacyclin. Arch. Biol. Med. Exp. 22:379–385 (1989).

    PubMed  CAS  Google Scholar 

  21. O. Koksel, M. B. Kaplan, A. Ozdulger, L. Tamer, U. Degirmenci, L. Cinel, M. Basturk, and A. Kanik. Oleic acid-induced lung injury in rats and effects of caffeine acid phenethyl ester. Exp. Lung Res. 31:483–496 (2005).

    Article  PubMed  CAS  Google Scholar 

  22. R. Ivarsen, and R. Broderson. Displacement of bilirubin from adult and newborn serum albumin by a drug and fatty acid. Dev. Pharmacol. Ther. 12:19–29 (1989).

    PubMed  CAS  Google Scholar 

  23. W. W. K. Koo, and E. E. Cepeda. Parenetral nutrition in neonates. In J. L. Rombeau, and R. H. Rolandelli (eds.). Parenteral Nutrition, 3rd ed., Saunders, Philadelphia, PA, 2001, pp. 463–475.

    Google Scholar 

  24. British Pharmacopeia. Her Majesty’s Stationary Office, London, Volume II, 1980, p. 580.

  25. D. F. Driscoll, F. Etzler, T. A. Barber, J. Nehne, W. Niemann, and B. R. Bistrian. Physicochemical assessments of parenteral lipid emulsions: light obscuration versus laser diffraction. Int. J. Pharm. 219:21–37 (2001).

    Article  PubMed  CAS  Google Scholar 

  26. D. F. Driscoll. Examination of selection of light-scattering and light-obscuration acceptance criteria for lipid injectable emulsions. Pharm. Forum 30:2244–2253 (2004).

    Google Scholar 

  27. D. F. Driscoll. The clinical significance of particle-sizing measurements in the safe use of intravenous fat emulsions. J. Dispers. Sci. Tech. 23:679–687 (2002).

    Article  CAS  Google Scholar 

  28. D. F. Driscoll, A. P. Silvestri, J. Nehne, K. Klütsch, B. R. Bistrian, and W. Niemann. The physicochemical stability of highly concentrated total nutrient admixtures (TNAs) intended for fluid-restricted patients. Am. J. Health-Syst. Pharm. 63:79–85 (2006).

    Article  PubMed  CAS  Google Scholar 

  29. Particulate matter in injections (chapter <788>). 2006 United States Pharmacopeia 29/National Formulary 24, The United States Pharmacopeial Convention, Rockville, MD, USA, pp. 2722–29.

  30. D. F. Driscoll, J. Nehne, H. Peterss, K. Klütsch, B. R. Bistrian, and W. Niemann. Physical assessments of lipid injectable emulsions via microscopy: a comparison to methods proposed in USP chapter <729>. Int. J. Pharm. Compd. 10:309–315 (2006).

    CAS  Google Scholar 

  31. C. Washington, and T. Sizer. Stability of TPN admixtures compounded from lipofundin S and aminoplex amino-acid solutions: comparison of laser diffraction and Coulter counter droplet size analyses. Int. J. Pharm. 83:227–231 (1992).

    Article  CAS  Google Scholar 

  32. F. A. Sayeed, M. G. Tripp, K. B. Sukumaran, B. A. Mikrut, H. A. Stelmach, and J. A. Raihle. Stability of various total nutrient admixture formulations using liposyn II and aminosyn II. Am. J. Hosp. Pharm. 44:2280–2286 (1987).

    PubMed  CAS  Google Scholar 

  33. L. Bullock, J. F. Fitzgerald, and W. V. Walter. Emulsion stability in total nutrient admixtures containing pediatric amino acid formulations. J. Parenter. Ent. Nutr. 16:64–68 (1992).

    Article  CAS  Google Scholar 

  34. R. C. Mehta, L. F. Head, A. M. Hazrati, M. Parr, R. P. Rapp, and P. P. DeLuca. Fat emulsion particle-size distribution in total nutrient admixtures. Am. J. Hosp. Pharm. 49:2749–2755 (1992).

    PubMed  CAS  Google Scholar 

  35. D. F. Driscoll, M. N. Bacon, and B. R. Bistrian. The effects of filtration on lipid particle size distribution in total nutrient admixtures. J. Parenter. Ent. Nutr. 20:296–301 (1996).

    Article  CAS  Google Scholar 

  36. D. F. Driscoll, M. N. Bacon, and B. R. Bistrian. Physicochemical stability of two different types of intravenous lipid emulsion as total nutrient admixtures. J. Parenter. Ent. Nutr. 24:15–22 (2000).

    Article  CAS  Google Scholar 

  37. D. F. Driscoll, K. Giampietro, D. P. Wichelhaus, H. Peterss, J. Nehne, W. Niemann, and B. R. Bistrian. Physicochemical stability assessments of lipid emulsions of varying oil composition. Clin. Nutr. 20:151–157 (2001).

    Article  PubMed  CAS  Google Scholar 

  38. D. F. Driscoll and B. R. Bistrian. The effects of packaging containers on the large-diameter tail of the globule size distribution (GSD) of lipid emulsions. Clin. Nutr. 24:699 (2005), P330.

    Article  CAS  Google Scholar 

  39. D. F. Driscoll, A. P. Silvestri, B. R. Bistrian, and B. A. Mikrut. All-in-one stability differences with lipid packaged in glass vs. plastic containers. Clin. Nutr. 24:700 (2005), P331.

    Article  CAS  Google Scholar 

  40. R. Geyer. Parenteral nutrition. Physiol. Rev. 40:150–186 (1960).

    PubMed  CAS  Google Scholar 

  41. G. Olivecrona, and T. Olivecrona. Clearance of artificial triacylglycerol particles. Curr. Opin. Clin. Nutr. Metab. Care 1:143–151 (1998).

    Article  PubMed  CAS  Google Scholar 

  42. D. F. Driscoll, P. R. Ling, W. C. Quist, and B. R. Bistrian. Pathological consequences from the infusion of unstable lipid emulsion admixtures in guinea pigs. Clin. Nutr. 24:105–113 (2005).

    Article  PubMed  CAS  Google Scholar 

  43. D. F. Driscoll, P. R. Ling, and B. R. Bistrian. Hepatic responses following infusion of pharmaceutically unstable lipid injectable emulsions as all-in-one mixtures into rats. Clin. Nutr. (2006), In press.

  44. K. J. Hamawy, L. L. Moldawer, M. Georgieff, A. J. Valicenti, V. K. Babayan, B. R. Bistrina, and G. L. Blackburn. The effect of lipid emulsions on reticuloendothelial system function in the injured animal. J. Parenter. Ent. Nutr. 9:559–565 (1985).

    Article  CAS  Google Scholar 

  45. D. L. Seidner, E. A. Mascioli, N. W. Istfan, K. A. Porter, K. Selleck, G. L. Blackburn, and B. R. Bistrian. The effects of long chain triglyceride emulsions on reticuloendothelial system function in humans. J. Parenter. Ent. Nutr. 13:614–619 (1989).

    Article  CAS  Google Scholar 

  46. G. L. Jensen, E. A. Mascioli, D. L. Seidner, N. W. Istfan, A. M. Domnitch, K. Selleck, V. K. Babayan, G. L. Blackburn, and B. R. Bistrian. Parenteral infusion of long and medium chain triglycerides and reticuloendothelial system function in man. J. Parenter. Ent. Nutr. 14:467–471 (1989).

    Article  Google Scholar 

  47. K. M. Jasnosz, J. J. Pickeral, and S. Graner. Fat deposits in the placenta following maternal total parenteral nutrition with intravenouslipid emulsion. Arch. Pathol. Lab. Med. 119:555–557 (1995).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Harvard Medical School, Boston, Massachusetts, USA

    David F. Driscoll

  2. Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Boston, USA

    David F. Driscoll

Authors
  1. David F. Driscoll
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David F. Driscoll.

Additional information

Dr. Driscoll is a Consultant and/or Researcher in the area of lipids for AstraZeneca, B. Braun, Biolink and Hospira companies.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Driscoll, D.F. Lipid Injectable Emulsions: Pharmacopeial and Safety Issues. Pharm Res 23, 1959–1969 (2006). https://doi.org/10.1007/s11095-006-9092-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-006-9092-4

Key words

Search

Navigation